Improving the response to molecular targeting of the TRAIL death receptors in colon cancer cells
PhD ceremony: Mr. B.E. Pennarun, 13.15 uur, Academiegebouw, Broerstraat 5, Groningen
Thesis: Improving the response to molecular targeting of the TRAIL death receptors in colon cancer cells
Promotor(s): prof. J.H. Kleibeuker, prof. E.G.E. de Vries
Faculty: Medical Sciences
It is important to develop new therapeutic options that will contribute to the improvement of colorectal cancer treatment. Chemotherapy can induce programmed cell death (apoptosis) in cancer cells. The apoptotic pathway, which is mediated by the mitochondria, is often disrupted in therapy-resistant cancer cells. An alternate route can be used to induce apoptosis in cancer cells, by using tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to activate the so-called “death receptors “at the cell membrane. In this thesis, we investigate which chemotherapeutic agents can increase the response to TRAIL in cancer cells, and the role played by the death receptors TRAIL-R1 and TRAIL-R2 in these effects.
Last modified: | 13 March 2020 01.15 a.m. |
More news
-
27 August 2024
UMCG gaat onderzoeksfaciliteiten beschikbaar stellen voor geneesmiddelenontwikkeling
Om de beschikbaarheid en effectiviteit van geneesmiddelen in Nederland te verbeteren gaat het UMCG het bedrijf G² Solutions opzetten. Dit bedrijf moet ervoor gaan zorgen dat belangrijke technologische ontwikkelingen op het gebied van DNA sequencing...
-
17 July 2024
Veni-grants for ten researchers
The Dutch Research Council (NWO) has awarded a Veni grant of up to €320,000 each to ten researchers of the University of Groningen and the UMCG. The Veni grants are designed for outstanding researchers who have recently gained a PhD.
-
16 July 2024
Medicine still subjects to male bias
Aranka Ballering studied the course of illness in people with common symptoms. One of the most striking findings to emerge from her research was that on average, women have a different – and less extensive – course of illness than men.